BioN­Tech is spear­head­ing an mR­NA vac­cine de­vel­op­ment pro­gram for malar­ia, with a tech trans­fer planned for Africa

Flush with the suc­cess of its mR­NA Covid-19 vac­cine, BioN­Tech is now gear­ing up for one of the biggest chal­lenges in vac­cine de­vel­op­ment — which comes with­out po­ten­tial prof­it.

The Ger­man mR­NA pi­o­neer says it plans to work on a jab for malar­ia, then trans­fer the tech to the African con­ti­nent, where it will work with part­ners on de­vel­op­ing the man­u­fac­tur­ing ops need­ed to make this and oth­er vac­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER